Physicians' Academy for Cardiovascular Education

Innovation

News, updates and resources on novel developments on the forefront of clinical science in cardiovascular medicine.

Learn more about the mission of PACE-CME

3' education - Aug. 31, 2018

CV outcomes with a PCSK9 inhibitor: FOURIER study

3' education - Mar. 16, 2017

Careful implementation of PCSK9 inhibitors in clinical practice

10' education - Aug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)

Promising results in pivotal trials of novel lipid-modifying drugs

3' education - Dec. 12, 2016 - Amsterdam, The Netherlands - Prof. John JP Kastelein, MD (AMC Amsterdam, The Netherlands)

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

3' education - Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada

Oral anticoagulation in daily clinical practice in varous patient populations

10' education - Oct. 6, 2016 - The Netherlands - Prof. Chris Granger, MD (Durham, NC, USA) and Marc Brouwer, MD (Nijmegen, The Netherlands)
##SCROLLER_ITEMS_FULL_TITLE##

Peak VO2 maintained in HF patients on IV iron therapy

3' education - Nov. 22, 2016 - AHA 2016 - Dirk Jan van Veldhuisen, MD (UMC Groningen, The Netherlands)
##SCROLLER_ITEMS_FULL_TITLE##

New class of lipid-lowering medication shows lasting LDL-c lowering in dose-finding study

3' education - Nov. 22, 2016 - Kausik Ray, MD - Imperial College London, United Kingdom
##SCROLLER_ITEMS_FULL_TITLE##

Brief update on various pharmacotherapeutic strategies to lower CV risk

3' education - Nov. 21, 2016 - AHA 2016 - Prof. Wouter Jukema, MD (LUMC Leiden, The Netherlands)

What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Silvio E Inzucchi (New Haven, CT, USA)
##SCROLLER_ITEMS_FULL_TITLE##

Customising therapy approach in ACS based on underlying pathology seems promising

3' education - Oct. 21, 2016 - ESC - 2016 Rome - Ik-Kyung Jang, MD - Massachusetts General Hospital, Boston, MA, USA
##SCROLLER_ITEMS_FULL_TITLE##

A changing treatment paradigm in diabetes

3' education - July 30, 2016 - Bangkok, Thailand - Richard E. Pratley, MD (Florida Hospital Diabetes Institute, Orlando, FL, USA)

SGLT2 inhibition in diabetic kidney disease

3' education - Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)

Novel small molecule that inhibits PAI-1 in development to slow vascular aging

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Douglas E. Vaughan, MD - Chicago, IL, USA

New therapies for type 2 diabetes show CV benefit beyond their glucose-lowering effect

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Silvio E. Inzucchi, MD - New Haven, CT, USA
##SCROLLER_ITEMS_FULL_TITLE##

Attenuating inflammation by inhibition of p38 MAP-kinase does not reduce CV endpoints in LATITUDE TIMI-60

3' education - Apr. 11, 2016 - ACC 2016, Chicago, IL, USA - Michelle O'Donoghue
##SCROLLER_ITEMS_FULL_TITLE##

How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?

10' education - Mar. 16, 2016 - Boston, MA, USA - Prof. Deepak Bhatt

Changing views on mechanisms of atherosclerosis

10' education - Feb. 12, 2016 - Boston, MA, USA - Prof. Peter Libby (Boston, MA, USA)
##SCROLLER_ITEMS_FULL_TITLE##

Inflammation and CV risk: Beyond statins in the treatment of atherosclerosis

3' education - Mar. 8, 2016 - Boston, MA, USA - Paul M Ridker
##SCROLLER_ITEMS_FULL_TITLE##

Impacting lipid disorders through personalised healthcare

3' education - Feb. 2, 2016 - VBWG, Orlando - Daniel J. Rader, M.D.
##SCROLLER_ITEMS_FULL_TITLE##

HF Summit : innovation in clinical care in heart failure

10' education - Oct. 31, 2015 - Barcelona, Spain - Prof. Adriaan Voors and Prof. Martin Cowie
##SCROLLER_ITEMS_FULL_TITLE##

Novel insights and innovations in targeting the neurohumoral system

3' education - Oct. 31, 2015 - HF Summit, Barcelona, Spain - Dr. Peter van der Meer
##SCROLLER_ITEMS_FULL_TITLE##

Accumulating clinical data on PCSK9 inhibition: What are the key lessons?

10' education - Sep. 30, 2015 - ESC 2015 London - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
##SCROLLER_ITEMS_FULL_TITLE##

Lipid Management 2020: A glance at the future

10' education - Sep. 24, 2015
##SCROLLER_ITEMS_FULL_TITLE##

PARAMETER: heart failure agent to treat hypertension

3' education - Sep. 1, 2015 - ESC - Londen 2015 - Bryan Williams
##SCROLLER_ITEMS_FULL_TITLE##

Pharmacodynamics of investigational pre-beta HDL-mimicking agent

3' education - May 24, 2015 - ISA2015, Amsterdam - Eralp Bellibas
##SCROLLER_ITEMS_FULL_TITLE##

Reassuring safety data with investigational lipid-modifying agent

3' education - May 24, 2015 - ISA2015, Amsterdam - David Kallend
##SCROLLER_ITEMS_FULL_TITLE##

Studying the cardioprotective properties of the phosphatidylserine-component of HDL

3' education - May 24, 2015 - ISA2015, Amsterdam - Dr. Anatol Kontush
##SCROLLER_ITEMS_FULL_TITLE##

The effects of a PCSK9-inhibitor on various lipid fractions

3' education - May 24, 2015 - ISA2015, Amsterdam - Gisette Reyes-Soffer
##SCROLLER_ITEMS_FULL_TITLE##

New, more potent chemical agent to lower triglyceride levels

3' education - May 24, 2015 - ISA2015, Amsterdam - Harold Bays

Learn more about the mission of PACE-CME

3' education - Aug. 31, 2018
Learn more about the mission of PACE-CME

Learn more about PACE-CME, our mission, our programmes and our cardiovascular educational services and resources

Inflammatory response is activated in end stage HF: a potential new therapeutic target?

News - Apr. 24, 2018

A small study found antibodies in plasma and heart muscle of end-stage heart failure patients, and more so if HF was caused by ischemic heart disease than by cardiomyopathy.

First-in-class cholesterol synthesis inhibitor meets primary endpoint in phase 3 study

News - Mar. 7, 2018

Phase 3 study data with bempedoic acid show 28% additional LDL-c lowering on background therapy and 33% reduction of hsCRP in patients with atherosclerotic CVD or at high risk for ASCVD.

Development of a cheaper, small biologic alternative to PCSK9 antibodies to lower LDL-c

News - Mar. 6, 2018

A preclinical study shows that DS-9001a interferes with PCSK9 binding to the LDL receptor and PCSK9-mediated LDLR degradation, and lowers LDL-c, and it is produced in a microbial production system.

New antidiabetic agent favorably affects glucose regulation and lipid profile

News - Mar. 6, 2018

12-Week treatment with GPR119 agonist DS-8500a lowers HbA1c, FPG and 2hPPG as compared with placebo, albeit to a lesser extend than sitagliptin, but it also lowered total cholesterol, LDL-c and TG.

Preclinical and clinical studies strengthen the promise of ANGPTL3 as a therapeutic target

Literature - May 30, 2017

Genetic and therapeutic antagonism of angiopoietin-3 in humans and mice improved lipid profiles and lowered CV risk, and oligonucleotide-based inhibition of Angptl3 in mice slowed atheroprogression.

Monoclonal antibody to ANGPTL3 receives FDA Breakthrough Therapy designation for HoFH

News - Apr. 11, 2017

Evinacumab is directed against angiopoietin-like protein 3, which acts as an inhibitor of lipoprotein lipase and endothelial lipase. Positive interim phase 2 results with evinacumab have been reported in HoFH.

Long-term sustained BP reductions with baroreflex activation therapy

Literature - Mar. 27, 2017 - de Leeuw PW et al. - Hypertension 2017;69: published online ahead of print

Baroreflex activation therapy lowers BP in the long-term, in treatment-resistant hypertensive patients, particularly in those with HF and preserved ejection fraction.

No effect of PCSK9 inhibitor on cognitive functioning in CVD patients, even at LDL-c <25 mg/dL

Presented at ACC.17 by Robert P. Giugliano

News - Mar. 18, 2017

ACC 2017 No difference in cognitive function was seen between evolocumab and placebo-treated patients in the EBBINGHAUS trial. No cognitive decline was seen over time in either treatment group.

Sustained LDL-c lowering up to 360 days with siRNA directed against PCSK9 in phase 2 study

Presented at ACC.17 by Kausik Ray

News - Mar. 16, 2017

ACC 2017 Inclisiran, which prevents PCSK9 protein production, resulted in long-term LDL-c lowering after two doses of siRNA, without safety concerns, in the ORION-1 study.

CV outcomes with a PCSK9 inhibitor: FOURIER study

3' education - Mar. 16, 2017
Marc S. Sabatine (Boston) presented the FOURIER-study, which evaluated a PCSK9 inhibitor during two years in over 27000 high-risk patients. LDL-c was reduced by 59%. Both the primary and the secundary clinical endpoint were significantly reduced.

ACC 2017 Marc S. Sabatine (Boston) presented the FOURIER-study, which evaluated a PCSK9 inhibitor during two years in over 27000 high-risk patients. LDL-c was reduced by 59%. Both the primary and the secundary clinical endpoint were significantly reduced.

Unanticipated attenuation of LDL-c lowering response to humanised PCSK9 antibody over time

Presented at ACC.17 by Paul M. Ridker

News - Mar. 16, 2017
The SPIRE trial data show that treatment with humanised PCSK9 antibody bococizumab resulted in LDL-c lowering that was not stable over time, due to generation of anti-drug antibodies.

ACC 2017 The SPIRE trial data show that treatment with bococizumab resulted in LDL-c lowering that was not stable over time, due to generation of anti-drug antibodies.